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To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were
sequentially immunized with vpunef SHIV-4 (vaccine-I) followed by vpuSHIVPPC (vaccine-II). Despite the absence of
virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood
mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies
against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well
as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the
vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a
58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge,
with a mixture of three challenge viruses, SHIVKU, SHIV89.6P, and SIVmacR71/17E. Two mock-vaccinated control animals
inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia,
and precipitous loss of CD4 T cells. The control animals did not develop any immune responses and succumbed to AIDS
between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by
the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was
two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates.
Vaccinated animals maintained normal CD4 T cell levels throughout the study. Challenge with pathogenic viruses caused
massive anamnestic responses as determined by quantitation of virus-specific CD4 and CD8 T cells by intracellular IFN-
staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has becomeINTRODUCTION
The slow progress in development of a successful
AIDS vaccine may be attributed, in part, to the fact that
definitive immunological correlates of protection are not
completely understood (Letvin, 1998) and that HIV con-
tinues to grow in the presence of vigorous immune
response by constantly evolving mutant viruses that es-
cape preexisting immune responses (McMichael, 1998;
Stipp et al., 2000; Allen et al., 2000a,b). However, it is now
becoming clear that virus-specific cytotoxic T lympho-
cytes (CTLs) can play a major role in controlling produc-
tive infection. Recently, it has been shown that CD8 T
cell depletion in SIV-infected rhesus macaques resulted
in massive enhancement of viral replication (Schmitz et
al., 1999; Jin et al., 1999). This has strengthened a con-
sensus that a suitable vaccine must be capable of in-
1 To whom correspondence and reprint requests should be addressedducing strong CTL responses. Virus-specific neutralizing
antibodies may also be valuable since passive immuni-
zation studies have shown that these antibodies prevent
infection (Burton et al., 2001; Parren and Burton, 2001;
Mascola et al., 1999, 2000; Shibata et al., 1999).
Pathogenic chimeric simian human immunodeficiency
viruses (SHIV) have been extensively used as challenge
viruses to study the biology and efficacy of candidate
vaccines in macaque model of human AIDS (Amara et
al., 2001; Barouch et al., 2000, 2001; Villinger et al., 2000;
Chen et al., 2001; Belyakov et al., 2001; Habel et al., 2000;
Matano et al., 2001). These viruses were typically pre-
pared by serial passage of molecular constructs of
SHIVs in macaques. The pathogenic derivative viruses
caused disseminated infection characterized by high-
level viremia and explosive replication in CD4 T cells
resulting in nearly total loss of this lymphocyte popula-
tion (Joag et al., 1996, 1997a,b, 1999; Luciw et al., 1995;
Reimann et al., 1996a,b; Igarashi et al., 1999).undetectable in lymph nodes of six of the seven vaccinate
animals. © 2002 Elsevier Science (USA)
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The live-attenuated vaccine approach is one of several
strategies being pursued to develop a successful vac-
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cine against AIDS (Letvin, 1998; Kumar and Narayan,
2001; Johnson and Desrosiers, 1998). This concept of
vaccine development is based on observations by sev-
eral groups that live-attenuated SIV strains, unlike patho-
genic SIV, replicated at a very low level and induced
strong and long-lasting immune responses. Immunized
animals were highly resistant to the effects of pathogenic
viruses given as challenge (Daniel et al., 1992; Johnson
et al., 1997, 1999; Connor et al., 1998; Gauduin et al., 1999;
Shibata et al., 1997). Our choice of live-attenuated vac-
cine was based on the observations of genetic changes
in vpu and nef genes that occurred in SHIV-4 during the
animal passage which yielded virulent SHIVKU-1 (McCor-
mick-Davis et al., 1998). Assuming that changes in two
auxiliary genes vpu and nef were vital for development of
the virulent virus, we deleted portions of both genes from
original SHIV-4 and used this virus as vaccine-I
(vpunefSHIV-4) (Joag et al., 1998b). We also selected
another nonpathogenic virus (SHIVPPC) and deleted 60 bp
from the vpu gene and used this also as a live-attenuated
vaccine (vpuSHIVPPC, vaccine-II) (Joag et al., 1998b). Our
earlier studies with these vaccine viruses showed that
vaccine-I did not productively replicate in pig-tailed ani-
mals but it induced responses that caused delay in onset
of disease from infection by SHIVKU-1, given as challenge.
However, these animals eventually succumbed to AIDS-
related complications within 2 years after challenge
(Stipp et al., 2000). Vaccine-II on the other hand, repli-
cated productively for a transient period and induced
long-lasting protection against pathogenic SHIVKU-in-
duced AIDS. These animals have remained healthy for
more than 3.5 years following challenge (Joag et al.,
1998b; Silverstein et al., 2000).
Since the success of the vaccine-II was thought to be
linked to its prior phase of productive replication, during
which it had the benefit of the presence of large amounts
of viral proteins to mount strong cellular immune re-
sponses, we designed another study to ask whether
prior infection in macaques with vaccine-I, followed by
inoculation with vaccine-II, would result in reduction of
the productive phase of replication of vaccine-II, and
whether such animals would have the same beneficial
effects of vaccine-II as seen in the earlier study. Seven
macaques were used in the study, and following immu-
nization, were challenged rectally with a mixture of three
pathogenic viruses, comprising homologous SHIVKU-2
and 2 heterologous pathogens, SHIV89.6P and SIVmacR71/
17E, a neurovirulent derivative of SIVmac251 (Sharma et
al., 1992).
RESULTS
Vaccine phase
Macaques immunized with vaccine-I followed by vac-
cine-II did not develop productive infection in peripheral
blood mononuclear cells (PBMC) or lose CD4 T cells.
Seven adult rhesus macaques were immunized subcu-
taneously with vaccine-I (104 TCID50) followed by oral
inoculation of 104 TCID50 of vaccine-II 4 months later. Two
control macaques were mock immunized with culture
medium. All nine animals were monitored for approxi-
mately 2 years for different hematological, immunologi-
cal, and virological parameters. None of the animals
developed infectious PBMC in the blood after inoculation
with vaccine-I or vaccine-II. To ensure that vaccine-II did
cause infection, seven vaccine animals were again in-
oculated with 104 TCID50 of vaccine-II by subcutaneous
route, 7 months after the first vaccine inoculation. How-
ever, none of the vaccinated animals developed infec-
tious PBMC in the blood. Nevertheless, viral infection
had been established in all seven animals because SIV-
gag DNA was detected in PBMC by PCR. The animals
were also monitored for CD4 T cell counts at 4-week
intervals, and none showed any loss. The mock-immu-
nized animals were negative for SIVgag DNA and vac-
cine virus-specific antibodies, and they maintained nor-
mal CD4 T cell profiles during the prechallenge phase
(results not shown).
Development of binding and neutralizing antibodies in
vaccinated and control macaques. Plasma samples were
examined for the presence of binding and neutralizing
antibodies 4 and 13 weeks after the first vaccination
(vaccine-I), at two time points (week 19 and 26) after oral
inoculation of vaccine-II, and at four time points (weeks
38, 54, 70, and 93) beginning 12 weeks after the second
vaccination with vaccine-II (Fig. 1). Vaccine-I induced
binding antibodies in all seven vaccinated animals and
was first detected at 4 weeks after inoculation. Vaccine-I
Env-specific antibody titers increased after vaccine-II
boost and showed peak values between weeks 26 and
38. These antibodies persisted throughout the vaccine
phase. All seven vaccinated animals also developed
vaccine-II Env-specific binding antibodies that became
detectable soon after the first vaccine-II inoculation. Vac-
cine-I- and -II-specific antibodies bound with the enve-
lope of homologous challenge virus (SHIVKU-2). Plasma
samples from five animals also recognized SHIV89.6P
envelope, but binding was significantly lower. These vac-
cine-induced antibodies did not bind with SIVmacR71/17E
envelope.
All seven animals developed vaccine-I-specific neu-
tralizing antibodies that continued to increase after vac-
cine-II boosts. Vaccine-II-specific neutralizing antibodies
became detectable in six of the seven animals, but only
after the second inoculation with vaccine-II. However,
neutralizing antibody titers against vaccine-II were lower
compared to those against vaccine-I. Following admin-
istration of the second dose of vaccine-II, five of the
seven animals developed cross-neutralizing antibody ti-
ters against SHIVKU-2 and two of these had lower titers
against SHIV89.6P. However, none of the vaccinated ani-
mals developed neutralizing antibodies against
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191LONG-TERM PROTECTION AGAINST SHIV AND SIV-INDUCED AIDS
SIVmacR71/17E. Two control animals did not develop any
neutralizing antibodies (results not shown).
Development of vaccine-specific CTLs that recognized
autologous CD4 T cells infected with SHIVKU-2, SHIV89.6P,
and SIV. We tested PBMC at 40 weeks after the last
immunization with vaccine-II (68 weeks after vaccine-I)
for their potential to lyse autologous Herpesvirus saimiri
(HS)-immortalized CD4 T cells infected with vaccine-II
virus homologous pathogenic virus SHIVKU-2, heterolo-
gous pathogenic virus SHIV89.6P, and SIVmacR71/17E. The
results of these experiments are shown in Fig. 2. The
effectors from all seven vaccinates recognized all four
viruses and caused specific lysis of targets infected with
the viruses. As expected, effectors from different ma-
caques displayed different degrees of lysis; macaque
RDu was the best, followed by RZc, RFc, RDz, RJv, ROd,
and RVr, respectively. In view of the results that CTLs
from different vaccinated animals recognized four differ-
ent viruses that contained different envelopes, we next
determined whether vaccine-induced CTLs were di-
rected only against one protein or different proteins en-
coded by the virus. To further characterize the antigen
specificity of the response, we used the same CTL ef-
fectors and tested them against autologous B-LCL tar-
gets infected with recombinant vaccinia viruses express-
ing HIV-1Env, SIVmac239-Env, SIV-Gag, and SIV-Pol. The
results of these experiments are illustrated in Fig. 2B.
The PBMC effectors from various animals showed spe-
cific lysis against HIV-1Env, SIV-Gag, and SIV-Pol, but
effectors from none of the seven animals caused signif-
icant lysis against SIV-Env (Fig. 2B). PBMC from the two
control macaques did not have CTL activity (data not
shown).
Vaccinated animals developed soluble virus inhibitory
factors. The vaccinated animals developed soluble viral
inhibitory factors that lasted for at least 59 weeks after
the last vaccine inoculation. Resting PBMC from different
macaques were stimulated with UV-irradiated autolo-
gous HS-transformed CD4 T cells infected with vaccine
virus for 3 days. After 3 days of stimulation, exogenous
IL-2 was added to the cultures and the cells were al-
lowed to grow for 4 additional days. On day 7 poststimu-
lation, the supernatant fluids were collected and tested
for their ability to inhibit replication of vaccine-II, SHIVKU-2,
SHIV89.6P, and SIVmacR71/17E. The results from these ex-
periments are shown in Fig. 3. PBMC supernatant from
macaque RDu had the maximum inhibitory activity
against all four viruses, followed by RFc, RVr, RZc, ROd,
RDz, and RJv, but none of the supernatant fluids (except
RDu) showed complete inhibition of any of the viruses.
Supernatant fluids from mock-vaccinated macaques RKk
and REs did not have inhibitory activity against any virus.
FIG. 3. Antigen-induced soluble viral inhibitory factor(s) from PBMC
of seven rhesus macaques immunized sequentially with vaccine-I
followed by vaccine-II and two control macaques. The soluble factors
were prepared from the seven vaccinated and two control animals by
cocultivation of PBMC, obtained 40 weeks after second vaccine-II
inoculation, with UV irradiated autologous HS-CD4 T cell clones
infected with vaccine-II as described under Materials and Methods.
Culture supernatants were collected on day 7, filtered through 0.22-M
membrane, and tested for their ability to block in vitro replication of
vaccine-II, SHIVKU-2, SHIV89.6P, and SIVmacR71/17E in CEM cells. Virus
replication in CEM cells was determined by measuring RT activity in 30
l supernatants. The results presented here depict inhibition in per-
centage considering virus production in the absence of PBMC super-
natants as 100%.
FIG. 2. CTL mediated lysis of autologous target cells infected with
vaccine-II and challenge viruses (A), and recombinant vaccinia viruses
expressing different viral proteins (B). The CTL effectors were prepared
from the seven vaccinated animals by cocultivation of PBMC, obtained
40 weeks after second vaccine-II inoculation, with UV irradiated autol-
ogous HS-CD4 T cell clones infected with vaccine-II as described
under Materials and Methods. They were tested after 2 weeks of initial
stimulation against mock-infected T cells and autologous T cells in-
fected with vaccine-II, SHIVKU-2, SHIV89.6P, and SIVmacR71/17E as well as
recombinant vaccinia viruses expressing HIV-1Env, SIV-Env, SIV-Gag,
and SIV-Pol. The effectors were tested in a 4-h chromium release assay
at E/T ratio of 80/1, 40/1, 20/1, and 10/1. Specific lyses obtained at E/T
ratio of 40/1 is shown above. The mean spontaneous counts in these
experiments were between 62 and 986 and the mean maximal release
between 416 and 9864.
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Challenge phase
Clinical outcome of challenge in control animals. The
two control and seven immunized animals were chal-
lenged 65 weeks after the last vaccine dose by intrarec-
tal inoculation of a virus cocktail containing more than
100 animal infectious doses of each of SHIVKU-2, SHIV89.6P,
and SIVmacR71/17E, respectively. A second intrarectal
challenge of the same cocktail was given 24 h later. The
two mock-vaccinated controls (REs and RKk) developed
highly productive infections as determined by infectious
cell assays (Fig. 4A) and plasma viral loads (Fig. 4B), and
lost 95% CD4 T cells within 3 weeks postchallenge
(Fig. 4C). On day 14, they had 2.1 107 and 4.9 107 viral
RNA copies/ml of plasma, respectively. In subsequent
weeks, both animals showed nearly total loss of CD4 T
cells from the PBMC. However, viral RNA loads remained
high. These animals progressed to clinical AIDS and lost
25% body weight within 6 weeks after challenge. Both
animals developed neurological signs (hyperreactivity,
movement-coordination, hand tremor, and balance).
They were euthanized at weeks 6 and 7, and histopatho-
logical examination of their tissues showed meningitis,
mild encephalitis, and severe depletion of CD4 T cells
from lymphoid tissues. Infectious virus was isolated from
PBMC, lymph node cells, and from 10% homogenates of
spleen, lung, liver, and brain. PCR analyses of total cel-
lular DNA from different organs showed the presence of
SHIVKU-2, SHIV89.6P, and SIVmacR71/17E DNA in all organs
except brain. Remarkably, PCR examination of nine re-
gions of the brains of these two animals showed the
presence of only SIVmacR71/17E DNA (results not shown).
The reason for this exclusive infection in the CNS by SIV
is not clear.
Clinical outcome of the challenge in vaccinated ani-
mals. All seven vaccinated macaques developed produc-
tive virus replication in the PBMC after challenge with
SHIVKU-2, SHIV89.6P, and SIVmacR71/17E. These animals
showed peak virus replication at week 2 to 3 postchal-
lenge, and the number of infectious cells ranged be-
tween 10 and 10,000/106 PBMC (Fig. 5A). Viral RNA in
plasma was detectable only in six of the seven animals
(Fig. 5B) and peak viral loads ranged between 770 and
1.7  105 RNA copies/ml. There was a general correla-
tion between infectious PBMC and plasma viral RNA
since peak values were observed at the same time
points. After ICA tests became negative, the plasma viral
RNA loads fell below 104 copies Eq/ml. Three animals
(RFc, RVr, and RZc) controlled the productive virus repli-
cation quickly and viral RNA became undetectable by
week 4. ROd had a peak viral load of 5100 copies/ml and
showed productive virus replication until week 6 post-
challenge. The two other vaccinates, RDz and RJv, had
peak viral loads of 1.7 and 1.6  105 copies/ml, respec-
tively, and showed productive virus replication for at least
28 weeks after challenge. Viral RNA was not detected
from any of the plasma samples taken from the seventh
vaccinate, Rdu. At week 61, when the last real time
RT-PCR analysis was performed, macaque RJv was the
only vaccinated animal that was positive for viral RNA
(440 copies/ml plasma) (Fig. 5B). None of these vacci-
nated animals lost CD4 T cells through the 73 weeks
postchallenge observation period (Figs. 5C and 5D).
Persistence of challenge virus and viral DNA in lymph
nodes: Specificity and sensitivity of primers. To evaluate
the specificity and sensitivity of the primers (Fig. 6), we
used DNA from CEM174 cells infected with vaccine-I,
FIG. 4. Cell-associated virus burden, plasma viral RNA loads, CD4
T cell profile, and CD4/CD8 ratio in two control macaques challenged
with cocktail of SHIVKU-2, SHIV89.6P, and SIVmacR71/17E. Two macaques,
RKk and REs, were mock immunized and challenged intrarectally twice,
1 day apart, with mixture of three pathogenic viruses. Cell-associated
viral burdens were measured by determining frequency of infectious
cells/106 PBMC (A), and viral RNA loads in plasma determined by real
time RT-PCR (B) as described under Materials and Methods. CD4 T
cell counts (C) were monitored by staining with mixture of MAbs
directed against CD3, CD4, and CD8 molecules. The absolute number
of CD4 T cells/l of blood was calculated by multiplying the percent-
age of lymphocyte subset with absolute number of lymphocytes/l of
blood from complete blood count (CBC). CD4/CD8 ratio (D) was calcu-
lated by dividing absolute number of CD4 T cells by absolute numbers
of CD8 T cells.
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vaccine-II, SHIVKU-2, SHIV89.6P, and SIVmacR71/17E, re-
spectively, as templates and performed PCR using prim-
ers shown in Table 1. Each set of primers specifically
amplified its respective challenge virus and did not am-
plify either of the two vaccine viruses (Fig. 6). SHIVKU-2
and SIVmacR71/17E primers detected one copy of viral
genome in 105 cells, whereas SHIV89.6P primers detected
one copy of viral genome in 104 cells (results not shown).
Since challenge viruses and viral RNA had become
undetectable in both PBMC and plasma, respectively, of
the vaccinated animals, we sought to determine whether
DNA of the viruses persisted in lymph nodes collected at
weeks 61 and 82 after challenge. Further, using isolate-
specific PCR amplification, we sought to assess which
viruses were present. Macaque RDu did not have detect-
able DNA of any of the viruses at either time point.
SHIVKU-2 DNA was present in the six other macaques at
week 61 and was still present in four of the six at week
82. Macaque RFc and RVr became negative for SHIVKU-2
DNA during the intervening period. SHIV89.6P DNA was
detectable in four (RDz, RJv, ROd, and RZc) of the seven
vaccinates at week 61, and by week 82, this DNA re-
mained detectable in lymph nodes of only two animals
(RDz and ROd). Thus, five of the seven vaccinates had no
detectable DNA of this virus in lymph nodes. SIVmacR71/
17E-specific DNA was detectable at both time points in
only one of the seven macaques (RJv) (Fig. 7). At week 82
we examined CD8-depleted lymph node cells for the
presence of infectious virus. Infectious virus was recov-
ered from three of the seven vaccinates. Two of the three
macaques yielded two challenge viruses (RJv, SHIVKU-2
and SHIV89.6P; ROd, SHIVKU-2, and SIVmacR71/17E). The
third macaque (RZc) yielded only SHIVKU-2 (results not
shown).
Immunological studies
Neutralizing antibody responses during the postchal-
lenge period. At the time of challenge, all seven vacci-
nated animals had neutralizing antibodies against vac-
cine-I virus, and six of the seven had neutralizing anti-
bodies against vaccine-II and SHIVKU-2. The challenge
with pathogenic viruses resulted in a strong boost in
antibodies against vaccine-I, vaccine-II, and SHIVKU-2
(Fig. 8). These antibodies persisted throughout the 78-
week postchallenge observation period. The seventh
macaque did not have detectable neutralizing antibodies
FIG. 6. Specificity of SHIVKU-2, SHIV89.6P, and SIVmacR71/17E primers.
CEM cells were infected with vaccine-I, vaccine-II, SHIVKU-2, SHIV89.6P,
and SIVmacR71/17E. Three days following infection cells were har-
vested, and total cellular DNA extracted as described under Materials
and Methods. Total cellular DNA (0.5 g) was used as template in a
nested/heminested PCR using different sets of primers shown in Table
1. Aliquots of second round PCR electrophoresed on 1.5% agarose gel,
and DNA was visualized by ethidium bromide staining. Lanes are
marked in terms of DNA template and primers used for the PCR.
FIG. 5. Cell-associated virus burden, plasma viral RNA loads, CD4
T cell profile and CD4/CD8 ratio in seven vaccinated macaques chal-
lenged with cocktail of SHIVKU-2, SHIV89.6P, and SIVmacR71/17E. Seven
macaques, RDu, RDz, RFc, RJv, ROd, RVr, and RZc, were immunized
sequentially once with vaccine-I followed by two immunizations with
vaccine-II, and challenged intrarectally twice, 1 day apart, with mixture
of three pathogenic viruses. Cell-associated viral burdens (A), viral RNA
loads in plasma (B), CD4 T cell counts (C), and CD4/CD8 ratio were
determined for a total 73 weeks, postchallenge period, as described in
legend of Figure 4.
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against vaccine-II and SHIVKU-2 at the time of challenge,
but it developed these antibodies to the two viruses after
challenge. One of the seven vaccinated animals had
SHIV89.6P-specific neutralizing antibodies at the time of
challenge, and this animal showed an anamnestic re-
sponse to this virus after challenge. Five others devel-
oped these antibodies only after challenge. Interestingly,
macaque RDu that showed the strongest resistance to
replication of the challenge viruses failed to develop
neutralizing antibodies against SHIV89.6P. Similarly none
of the seven vaccinated animals had anti-SIVmacR71/17E-
neutralizing antibodies at the time of challenge and they
did not develop these antibodies during the 78-week
postchallenge observation period (Fig. 8), even though
they controlled replication of this virus very efficiently.
Neither of the two control animals developed any neu-
tralizing antibodies against any of the three challenge
viruses (results not shown).
CTL activity during the postchallenge period. CTL ac-
tivity against vaccine-II and the three challenge viruses
was examined 3, 12, 28, 50, 61, and 70 weeks after
challenge. All seven vaccinated animals developed in-
creased CTLs against vaccine-II, SHIVKU-2, SHIV89.6P, and
SIVmacR71/17E, and these responses were directed
against Env, Gag, Pol, and Nef proteins (Table 2). The
CTLs were present in all seven animals and were al-
ready present at week 3 after challenge when the first
assay was done. There was no definitive correlation
between percentage virus-specific lysis and viral loads
in PBMC or plasma. Nonetheless, these cells persisted
for at least 70 weeks after challenge. The two control
animals did not develop challenge virus-specific CTLs
(results not shown).
Quantitation of virus specific-CD4 and CD8 T cell
responses after challenge. The virus-specific CD4 and
CD8 T cells were quantified by intracellular IFN-
staining in response to stimulation with irradiated au-
tologous B-LCL after overnight infection with recombi-
nant vaccinia viruses expressing HIV-1Env, SIV-Gag,
SIV-Pol, and SIV-Nef. This assay was performed once
during the vaccine phase (60 weeks after the second
vaccine-II inoculation) and at weeks 8, 24, 39, and 74
after challenge with the pathogenic viruses. The re-
sults of these experiments are shown in Fig. 9. Virus-
specific CD4 and CD8 T cells were detectable in all
seven vaccinated animals even at 60 weeks after the
last immunization. The virus-specific CD4 T cells
TABLE 1
Sequences of the Primers Used for Amplification of SHIVKU-2, SHIV89.6P, and SIVmacR71/17E
Target virus PCR Primer Sequence Product sizea (bp)
SHIVKU-2 Ist round Sense 5-
6825GAT-AGA-CTA-ATA-GAA-AGA-GCA-GAA-GAC6851-3
Antisense 5-7797TGG-TCC-TCT-CTG-GAT-ACG-GAT-T7776-3
II round Sense 5-7098CCC-ACA-AGA-AGT-AGT-ATT-GGT-71183
Antisense 5-7797TGG-TCC-TCT-CTG-GAT-ACG-GAT-T7776-3 699
SHIV89.6P Ist round Sense 5-
6303GAT-AGA-CTA-ATA-GAA-AGA-GCA-GAA-GAC6329-3
Antisense 5-7669GAT-GAA-CAT-CTA-ATT-TGT-CCT-G7648-3
II round Sense 5-7168CTG-AAG-ATT-TCA-CAG-ACA-ATG-T7189-3
Antisense 5-7669GAT-GAA-CAT-CTA-ATT-TGT-CCT-G7648-3 501
SIVmacR71/17 Ist round Sense 5-6854GTA-AGT-ATG-GGA-TGT-CTT-GG6873-3
Antisense 5-7748TCC-TAT-TAT-CCC-TAC-CAT-GCC-AG7726-3
II round Sense 5-6877TCA-GCT-GCT-TAT-CGC-CAT-CT6896-3
Antisense 5-7515GAC-TCT-TTG-ATA-ACA-GAA-GTG-TTA-CAG7489-3 638
a Product size indicates final molecular weight of the product amplified after second round PCR.
FIG. 7. Persistence of challenge virus-specific DNA in lymph nodes
of vaccinated animals challenged with cocktail viruses. Lymph node
biopsies were obtained from seven vaccinated macaques 61 and 82
weeks after challenge. Total cellular DNA was extracted, and 0.5 g
DNA was used in each PCR using primers specific for SHIVKU-2,
SHIV89.6P, and SIVmacR71/17E. Five microliters of second round PCR
product was electrophoresed on a 1.5% agarose gel and DNA bands
were visualized by ethidium bromide staining. Boxes on left marked
time and primer specificity, whereas animal names are mentioned on
the top.
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ranged between 0.8 and 1.34% of the total CD4 T cell
population, and virus-specific CD8 T cells ranged
between 0.8 and 1.56% of the total CD8 T cells in the
PBMC of vaccinated animals. Following challenge, the
animals developed massive anamnestic responses. At
week 8, postchallenge, approximately 10–30% of the
total CD4 and CD8 T cells were virus-specific.
These virus-specific CD4 and CD8 T cell popula-
tions declined gradually, and at the time of last quan-
tification, 74 weeks postchallenge, the frequency of
these cells ranged between 0.9 and 3.1%.
Vaccinated animals developed long-term soluble virus
inhibitory factors. At 3 and 61 weeks after challenge of the
animals, supernatant fluids of cultures of PBMC from all
seven vaccinated animals were tested for inhibition of rep-
lication of vaccine-II, SHIVKU-2, SHIV89.6P, and SIVmacR71/17E.
Results of these experiments are shown in Fig. 10. The
supernatant fluids from all seven vaccinated animals com-
pletely inhibited replication of all the four viruses. The virus
inhibition was complete and these factors were present at
least for 61 weeks when the last assay was done. Similar
fluids from infected control animals did not have soluble
virus inhibitory factor(s).
DISCUSSION
We used two nonpathogenic SHIVs from which acces-
sory genes had been deleted as live-attenuated vac-
cines, in an effort to protect rhesus macaques against
mucosal challenge with a mixture of homologous and
heterologous pathogenic SHIV and SIV isolates. Despite
the absence of direct virological evidence of productive
replication by either of the two vaccine viruses, the se-
quential immunization protocol resulted in infection and
development of long-lasting cellular and humoral im-
mune responses in all of the animals. These responses
were detectable as long as 14 months following the last
vaccine administration. Vaccine-induced responses cur-
tailed replication of the challenge viruses and helped in
reduction of concentrations of their RNA in plasma of all
of the animals. Further, levels of challenge virus DNA in
lymph nodes of several of the immunized animals were
reduced to levels below the assay detection thresholds.
We had shown previously that vaccine-II, but not vac-
cine-I, conferred long-term protection against AIDS in-
duced by homologous pathogenic virus SHIVKU. The pro-
tection achieved in the vaccine-II group was associated
with transiently productive replication of the vaccine vi-
rus. Although vaccine-I-induced immune responses did
not confer indefinite protection against pathogenic
SHIVKU given as challenge, the induced responses nev-
ertheless blunted the replication of challenge virus and
delayed the progression of animals to clinical disease
state at least by 1 year (Stipp et al., 2000). On the other
hand, animals infected with vaccine-II developed limited
productive infection and these animals resisted the dis-
ease caused by pathogenic challenge virus and have
remained healthy for nearly 4 years postchallenge (Joag
et al., 1998b; Silverstein et al., 2000; Kumar et al., unpub-
lished observations). In the present study we sought to
address whether prior immunization with vaccine-I
would curtail the replication of vaccine-II, whether the
protective efficacy of vaccination would be retained as
observed earlier (Joag et al., 1998b; Silverstein et al.,
2000), and whether the protection would be effective
against pathogenic heterologous viruses (Silverstein et
al., 2000). In seven animals immunized with the sequen-
FIG. 8. Persistence of neutralizing antibodies in seven vaccinated ma-
caques challenged with cocktail of SHIVKU-2, SHIV89.6P, and SIVmacR71/17E.
Neutralizing antibody titers were determined by preincubating different
dilutions of sequentially collected plasma samples in quadruplicate with
different vaccine and challenge viruses, followed by culture with C8166
cells for 7 days. The wells were scored for CPE and results are presented
as end-point neutralizing antibody titers against vaccine-I (}), vaccine-II
(), SHIVKU-2 (‚), SHIV89.6P (F), and SIVmacR71/17E ().
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tial vaccine regimen, there was no evidence of infectious
virus in the PBMC of any. However, the animals devel-
oped demonstrable vaccine-II-specific CD4 and CD8 T
cells, and functional CTL responses against vaccine-II
were detectable by intracellular IFN- staining and chro-
mium release assays, respectively. Although no infec-
tious vaccine virus was recovered from the PBMC of the
vaccinated animals, the presence of CTL responses in
these animals suggested the persistence of low-level
viral replication. Vaccine virus-specific CTLs caused spe-
TABLE 2
Long-Term CTLs in Macaques Immunize with Vaccine-I Followed by Vaccine-II and Challenged with Mixture of SHIVKU-2, SHIV89.6P and SIV
Macaque
Week
postchallenge
Percentage specific lysis againsta
Controlb SHIVKU-2
c SHIV89.6P
c SIVc HIV-1Envd SIV-Gagd SIV-Pold SIV-Nefd
RDu 3 0 52.1 19.2 37.6 34.1 24.6 9.3 NDe
12 0 43.6 30.5 32.5 16.1 16.2 7.7 50
28 0.7 66.7 67.8 51.2 20.9 47.4 42.1 31.6
50 0 16.1 41.7 39.9 ND ND ND ND
61 4 46 48.8 37.5 33.7 39.9 60 30.3
70 0 44 32.5 36.8 33.7 28.1 68 36.5
RDz 3 5.9 42.7 26.3 39.7 38.1 28.3 24.5 ND
12 0 53.3 26.1 38.3 38.9 38.9 40.1 34.7
28 0.2 48.8 36.1 80.2 34.3 44.1 28.3 30
50 0 30.2 29.7 27.9 ND ND ND ND
61 3.1 55.6 43.7 51 42.7 36.5 30.5 42.7
70 0.2 37.5 54.2 40.9 50.8 27.3 30.7 61.5
RFc 3 2.6 35 34.7 62.6 15.4 15.8 12 ND
12 0 36.9 28.5 31.3 26.8 33.5 23.7 24.2
28 1.7 70.2 53.1 45 ND 35.8 68.8 14.1
50 0 14.5 11.5 15.2 ND ND ND ND
61 0 55.7 58.1 50.1 75.4 63.5 44.6 57
70 0 48.4 52.6 44.4 37.5 43.4 44.5 25
RJv 3 2.4 32.8 50.6 54.2 26.6 16.1 29.7 ND
12 0 34.8 33.3 22.2 12 25 27.9 31.9
28 0 33.2 44 57.9 34.9 31.5 34.2 42.5
50 3.5 45.6 46.2 29.8 ND ND ND ND
61 0.2 51.8 50.9 58.5 60.8 80.3 33.9 63.3
70 0 48.4 27.7 20 32.4 51.7 40.6 38.7
ROd 3 1.4 44.2 28.2 43.4 17.1 2.3 25.3 ND
12 48.2 17.3 44.8 15.6 35.4 21.2 31
28 0 35.7 32 61 50.5 46.5 47.7 40.5
50 0 32.7 43.3 19.7 ND ND ND ND
61 0 52.8 67.1 55.6 33.1 58.6 67.4 41.9
70 2.3 26.3 50.5 38.4 45.3 39.6 40.6 50.1
RVr 3 0 66.6 28.8 26.2 50.4 29.7 50.8 ND
12 45.7 38.4 47.1 44.7 32.5 13.8 23.1
28 1 40.2 37.6 39.2 32.3 68.7 43.3 36.8
50 0 54.4 ND 15 ND ND ND ND
61 6.6 59.1 50.1 70.2 34.7 33.7 57.8 38.7
70 0.5 36.6 45.6 18.1 41.6 44.9 38.3 23.3
RZc 3 0 40.8 21.4 59.6 26.1 12 20.3 ND
12 0 34.9 37.1 55 27.7 33.9 37.8 17.8
28 0 51.8 47 54.5 39.9 55.8 37.3 55
50 ND ND ND ND ND ND ND ND
61 2.8 63.5 55.2 47.3 49.5 61.7 35.1 48.4
70 1.1 53.5 42 45.2 31.4 33.3 39.1 32.3
a PBMC effectors from different animals were tested against different targets at effector/target ratio of 80/1, 40/1, 20/1, and 10/1. The results shown
here are specific lysis obtained at effector/target ratio of 40/1. The mean spontaneous counts in these experiments ranged between 50 and 860, and
mean maximal count ranged between 330 and 3650.
b Specific lysis against control targets represents either uninfected autologous CD4 T cell clone or autologous B-LCLs mock-infected and used
as targets in 4-h chromium release assay.
c Autologous CD4 T cell clones were infected with SHIVKU-2, SHIV89.6P, or SIV for 3 days, labeled with [
51Cr], and used in cytotoxicity assays.
d Autologous B-LCLs were infected overnight with recombinant vaccinia virus expressing HIVEnv or SIVGag or SIVPol or SIVNef and used as targets.
e Not done.
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cific lysis of autologous CD4 T cells infected with
SHIVKU-2, SHIV89.6P, and SIVmacR71/17E, underscoring the
fact that CTL activity was either directed against con-
served epitope(s) in the envelope protein or the other
proteins common to the virus strains, Gag, Pol, and Nef.
All vaccinated animals developed vaccine-I and vac-
cine-II Env-specific binding antibodies that cross-reacted
with the envelope protein of homologous pathogenic virus
SHIVKU-2, and to a lesser extent cross-reacted with SHIV89.6P
envelope. However, vaccine-specific antibodies did not
cross-react with the envelope of SIVmacR71/17E, presumably
because of the extensive sequence disparity between the
envelope protein of the SIV and other viruses. Likewise, six
of the seven challenged vaccinates developed neutralizing
antibodies against both of the vaccine viruses. Five vacci-
nates developed neutralizing antibodies against SHIVKU-2,
and two developed neutralizing antibodies against
SHIV89.6P, respectively, suggesting that some of the neutral-
ization epitope(s) were conserved between vaccine-I and
-II, and SHIVKU-2 and SHIV89.6P. None of the animals devel-
oped neutralizing antibodies against SIV. This lack of neu-
tralization response again likely reflected the heterogeneity
between the envelopes of SHIVs and SIV.
The importance of virus-specific CD8 T cell re-
sponses has been indirectly shown in several studies in
HIV-infected individuals with the demonstration that vi-
rus-specific CTLs correlated with decline of plasma virus
burdens (Day et al., 2001; Walker and Korber, 2001; Goul-
der et al., 2001; Altfeld et al., 2001; Walker and Rosen-
berg, 2000). Similar correlations have been observed in
macaques infected with SIV and SHIV (Johnson and
Desrosiers, 1998; Cromwell et al., 2000; Kaur et al., 2000;
Joag et al., 1998b; Silverstein et al., 2000; Kumar et al.,
2001a,b), in which CTLs (Kaur et al., 2000; Joag et al.,
1998b; Silverstein et al., 2000; Kumar et al., 2001a,b)
correlated inversely with decline in virus replication. A
more direct role for the CTLs was shown in studies in
which depletion of CD8 T cells in SIV/SHIV-infected
macaques resulted in dramatic increases in plasma vire-
mia (Metzner et al., 2000; Schmitz et al., 1999; Jin et al.,
1999). The present study provides further insights into
the importance of T cell mediated responses. The vac-
cine viruses induced both humoral and cellular immune
responses that were present throughout the prechal-
lenge period, but the CMI responses probably were of
greater importance in controlling the challenge viruses
given subsequently. All animals developed vaccine virus-
specific neutralizing antibodies that were detectable at
the time of challenge, but these antibodies did not cross-
neutralize one or more of the challenge virus(es). In
contrast, vaccine-induced CTLs and soluble inhibitory
factor(s) showed activity against not only vaccine viruses
but also against all the challenge viruses, suggesting
FIG. 10. Postchallenge antigen-induced soluble viral inhibitory fac-
tor(s) from PBMC of seven vaccinated and two control macaques. The
soluble factors were prepared by cocultivation of PBMC, obtained at 3
(A) and 61 (B) weeks after challenge, with UV-irradiated autologous
HS-CD4 T cell clones infected with mixture of vaccine and challenge
viruses, as described under Materials and Methods. Culture superna-
tants were collected on day 7, filtered through 0.22-M membrane, and
tested for their ability to block in vitro replication of vaccine-II, SHIVKU-2,
SHIV89.6P, and SIVmacR71/17E in CEM cells. Virus replication in CEM
cells was determined by measuring RT activity in 30 l supernatants.
The results presented here depict inhibition in percentage considering
virus production in the absence of PBMC supernatants as 100%.
FIG. 9. Quantitation of virus-specific CD4 and CD8 T cells in ma-
caques immunized with vaccine-I and vaccine-II and challenged with
cocktail of SHIVKU-2, SHIV89.6P, and SIVmacR71/17E. Two million PBMC, col-
lected at 5 weeks before challenge and 8, 24, 39 and 74 weeks after
challenge, were stimulated with UV-irradiated autologous B-LCL infected
with mixture of recombinant vaccinia viruses expressing HIV-1Env, SIV-
Gag, SIV-Pol, and SIV-Nef for 12–14 h with 5 g/ml brefeldin-A for the last
6 h. The cells were then stained with antibodies against CD3, CD4, CD8,
and IFN-, and analyzed on FACS calibur. Percentage of CD4 IFN-, and
CD8 IFN- T cells with mock-stimulation (0.5%) was subtracted from
percentage of viral proteins-specific CD4, IFN-, and CD8 IFN- T
cells to calculate percentage population of specific cells.
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that the major role for these cellular immune responses
was containment of challenge virus replication.
The quantitative dissection of virus-specific cellular
immune responses has been revolutionized by several
recently introduced technologies. These include devel-
opment of tetrameric complexes of major histocompati-
bility complex class I (MHC-I) or MHC-II glycoproteins
and viral peptides for the direct-flow cytometric staining
of responding lymphocyte populations (Kuroda et al.,
1998; Barouch et al., 2001; Callan et al., 1998; Gallimore
et al., 1998), ELISPOT (Goulder et al., 2001; Lalvani et al.,
2001; van Baarle et al., 2001; Scheibenbogen et al., 2000;
Shacklett et al., 2000; Larsson et al., 1999; Corne et al.,
1999; Dunbar et al., 1998; Mayer et al., 1996), and intra-
cellular cytokine staining (Goulder et al., 2001; Marshall
et al., 2001; Belz et al., 1998; Stevenson et al., 1998). The
tetramer technology can only be used within the context
of MHC-I and specific viral epitopes, whereas ELISPOT
and intracellular cytokine (IFN-) staining can be used
for studies in outbred animals, without any prior knowl-
edge of MHC restriction elements, or the sequences of
defined CTL or Th epitopes. Furthermore, several studies
have shown comparable profiles between intracellular
IFN- staining and tetramer staining (Flynn et al., 1998;
Murali-Krishna et al., 1998). In view of the limited knowl-
edge regarding macaque MHC and T-helper/CTL
epitopes, ELISPOT and intracellular IFN- staining offer
a better means to quantitate virus-specific CTL or T-
helper responses in outbred macaques. We used intra-
cellular IFN- staining to quantify virus-specific cellular
responses. Our study indicated massive anamnestic
CD4 and CD8 T cell responses as measured by stain-
ing of PBMC for their ability to secrete interferon- in
response to stimulation with viral antigen. The presence
of 10–30% virus-specific CD4 and CD8 T cells pointed
to a clonal expansion of virus-specific T cells after chal-
lenge. The massive anamnestic response has also been
reported in another study (Allen et al., 2000b).
Earlier findings by several groups (Walker et al., 1986)
showing that soluble factors secreted by CD8 T cells
(CD8-SF) can block replication of the virus suggested
this as a possible mechanism contributing to control of
virus replication in our study. This noncytolytic function of
CD8 T cells has also been shown in HIV-1-infected
individuals and SIV-infected animals (Aubertin et al.,
2000; Lehner et al., 1996, 1999; Wang et al., 1998; Walker
et al., 1986; Garzino-Demo et al., 1999). Whereas earlier
reports had used nonspecific stimulation to identify CD8-
SF, we adopted the more clinically relevant strategy to
ask whether viral antigen could be important for inducing
production of inhibitory soluble factors. In a recent report
antigen-induced chemokine production in HIV-positive
individuals has been inversely correlated with the pro-
gression of clinical disease (Garzino-Demo et al., 1999).
Here, we have shown that vaccine viruses induced in-
hibitory factors that blocked replication of not only the
vaccine virus but also the challenge viruses. The ability
of PBMC to secrete these factors was sustained for a
long time and might have contributed to the elimination
of challenge viruses, after the latter had established
infection in lymph nodes.
Another interesting finding that emerged from this
study was that although SIVmacR71/17E is the most diver-
gent from the vaccine viruses in its nucleotide se-
quences, it was the easiest virus to be controlled. At the
time of challenge, vaccinated animals had neither SIV-
Env-specific CTL nor anti-SIV neutralizing antibodies.
Only SIV core-specific CTL and SIV-specific soluble in-
hibitory factors were detectable at the time of challenge.
On the other hand, SHIVKU-2 was the challenge virus that
had closest sequence homology to the vaccine viruses. At
the time of challenge, all seven animals not only had CTLs
directed against Env and core proteins and SHIVKU-2-
specific inhibitory factors, but several of them also had
SHIVKU-2-specific neutralizing antibodies. In spite of this,
SHIVKU-2-specific DNA persisted in lymph nodes of four of
the seven animals at 81 weeks after challenge, and two
of the seven animals are still harboring replication-com-
petent SHIVKU-2 at this time point. The reason for this is
unclear but may relate to intrinsic properties of SHIVKU-2
that made it harder to be controlled/eliminated compared
to SHIV89.6P and SIVmacR71/17E.
In summary we provide evidence that long-term pro-
tection against simultaneous challenge with homolo-
gous and heterologous SHIV and SIV is possible. The
protection seen in these animals can be characterized
not only by prevention of disease and reduction of viral
loads in plasma but by progressive reduction over time
of challenge virus DNA in PBMC and/or lymph nodes, in
some instances to below detectable levels. This effect
was probably mediated by a combination of neutralizing
antibodies, CTLs against different challenge viruses, and
soluble inhibitory factors. Similar results of DNA vaccine-
induced reduction of challenge virus replication have
been reported by others (Amara et al., 2001; Barouch et
al., 2000) but whether these vaccine strategies also re-
sulted in progressive elimination of challenge virus DNA
as seen in this study is not known as yet.
The final point emerging from this study was that a
graded course of immunization first with a more attenu-
ated virus followed by a less attenuated one may be an
effective way of reducing replication of highly effective
live vaccine viruses and thus reducing the chances of
reversion of vaccine viruses into pathogenic strains. This
approach, of using prior immunization to enhance the
safety of an attenuated virus vaccine strain, is broadly
similar to the current recommendation for pediatric polio
immunization, in which children receive killed polio virus
vaccine prior to being vaccinated with live-attenuated
polio virus vaccine (Wadsworth, 1999). Live-attenuated
vaccines have been among the more efficacious vac-
cines developed, and in nonhuman primate studies, live-
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attenuated SIV vaccines (Desrosiers, 1995; Johnson and
Desrosiers, 1998; Johnson et al., 1999), and SHIV vaccines
(Joag et al., 1998b; Silverstein et al., 2000), and this study
has shown levels of efficacy that have not been matched by
other vaccine approaches. However, safety is always a
major concern for live-attenuated vaccines and this con-
cern is amplified in contemplating a live-attenuated vaccine
for a pathogen such as HIV, for which an uncontrolled
infection could be fatal (Baba et al., 1999). The variation on
the sequential immunization approach described here, or
the fact that the live vaccine virus failed to become patho-
genic after serial passage in animals (Mackay et al., 2002),
reduced but did not eliminate concerns about use of live
virus vaccines against HIV. Nevertheless, these studies
provide further proof of concept data of the potential to
which nonlive vaccines could be aimed.
MATERIALS AND METHODS
Viruses
The construction of vaccine-I, vaccine-II, and deriva-
tion of SHIVKU-2 has been previously described (Joag et
al., 1998a,b). Vaccine-I was derived from nonpathogenic
SHIV-4, by deleting 60 bp from vpu and 205 bp from nef.
Vaccine-II was derived from another nonpathogenic virus
SHIVPPC by deleting 60 bp from vpu (Joag et al., 1998a).
SHIVKU-2 was derived from nonpathogenic SHIV-4 first by
serial passage in young pigtailed macaques (Joag et al.,
1996) followed by passage in rhesus macaques (Joag et
al., 1998b). Stock preparations of these viruses were
propagated in macaque PBMC. Infectivity of stocks of the
three viruses was assayed in C8166 cell cultures and
had titers of 104 (vaccine-I), 1.6  104 (vaccine-II), and
6.3  104 TCID50/ml (SHIVKU-2). SHIV89.6P was kindly pro-
vided by Dr. N. Letvin (Reimann et al., 1996a,b), and stock
virus was prepared by cultivation in mitogen-stimulated
macaque PBMC. The titer in C8166 cells was 4  108
TCID/ml. SIVmacR71/17E is a neurovirulent variant of
SIVmac251 (Sharma et al., 1992). Herpesvirus papio stock
was obtained by collecting supernatant fluid from a per-
sistently infected cell line S594 (provided by Dr. N. Letvin)
(Rabin et al., 1977). H. saimiri stock was obtained from
ATCC and propagated in owl monkey kidney cell cultures
as described previously (Kumar et al., 1999). The recom-
binant vaccinia viruses that were used to infect target
cells included vAbT299 (expressing HIV-1BH-10ENV lack-
ing 19 amino acids starting from position 42–60 at the
amino-terminus), vT60 (SIVmac239 Env  leader), vAbT252
(SIVmac251-GAG), vAbT258R (SIVmac251-POL), vAbT306
(SIVmac239 Nef), and NYCBH (wild-type vaccinia virus).
These viruses were kindly provided by Drs. D. Panicali
and G. Mazzara, Therion Biologics, Cambridge, MA. The
recombinant vaccinia viruses were propagated in HeLa
cell cultures. All virus stocks were maintained at 80°C
except for the challenge virus stocks which were stored
in liquid nitrogen.
Vaccination of macaques and challenge with SHIVKU-2,
SHIV89.6P, and SIVmacR71/17E
Nine 3- to 5-year-old rhesus macaques (Macaca mu-
latta) were obtained from the Yerkes Primate Center,
Atlanta, GA and maintained in the AAALAC-approved
Animal Facility of the University of Kansas Medical Cen-
ter. Seven animals were inoculated subcutaneously,
close to the inguinal and axillary lymph nodes, with 1 ml
of vaccine-I. Four months later, the animals received two
doses of 1 ml of vaccine-II (104 TCID50), given orally 1 day
apart. Three months following this, the animals were
administered a further inoculation of vaccine-II (104
TCID50), subcutaneously, because of failure to detect
infectious virus in PBMC following the oral inoculations.
Fifty-eight weeks after the third immunization, the vacci-
nated and two unvaccinated control animals were chal-
lenged twice, 1 day apart, by intrarectal route with a
mixture of undiluted SHIVKU-2, SHIV89.6P, and SIVmacR71/
17E stocks. The animals were bled regularly to monitor
CD4 T cell profiles, cell-associated as well as cell-free
viral loads in the blood, and cellular and humoral im-
mune responses to the different viruses.
Flow cytometry
Lymphocyte subset profiles were determined by stain-
ing for CD3, CD4, and CD8 surface markers, using the
whole-blood lysis technique (Wyand et al., 1996). Briefly,
10 l of the antibody mix against CD3, CD4, and CD8
(Becton–Dickinson) was added to 100 l of whole blood
and incubated for 1 h in the dark. Lysing solution (Bec-
ton–Dickinson) was then added and the samples were
incubated for another 10 min at room temperature.
Stained cells were fixed with 0.5% paraformaldehyde and
analyzed in a flow cytometer (Becton–Dickinson FACS
Calibur).
Viral load measurements
Plasma viral RNA levels were determined by real-time
reverse transcriptase PCR (ABI Prism 7700-sequence
detection system, Perkin–Elmer) essentially as de-
scribed previously (Lifson et al., 2001). The sensitivity of
this assay is 100 copy Eq/ml of plasma. The frequency of
infectious cells in blood was determined by inoculation
of serial 10-fold dilutions of PBMC into cultures of C8166
cells that were then observed for the development of
cytopathic effects (CPE) (Joag et al., 1998a,b). Results of
this infectious cell assay (ICA) are expressed as the
number of infectious cells per 106 PBMC.
Recovery of infectious virus from PBMCs and lymph
node cells
Two million LNMC CD4 T lymphocytes, enriched by
negative selection, were stimulated with PHA (1 g/ml)
for 2 days in 2 ml R-10 (RPMI-1640 containing 10% FBS,
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5 mM NaHCO3, and 50 g/ml gentomycin). The cells
were washed and cultured in R-10/IL-2 (R-10 containing
50 IU/ml recombinant interleukin-2) for 5 days. The su-
pernatant fluids were tested for viral cytopathocity in
C8166 cultures.
Detection of challenge virus DNA in lymph nodes of
challenged animals
DNA extracted from lymph nodes from challenged
animals was screened for the presence of DNA of dif-
ferent challenge viruses by PCR, using primers specific
for the envelope sequences of SHIVKU-2, SHIV89.6P, and
SIVmacR71/17E, respectively. The sequence of the primers
for first- and second-round amplifications, the location of
the primers in the viral genome, and the expected size of
the PCR products are shown in Table 1. Genomic DNA
(0.5 g) was used in the PCR mixture containing 4 mM
MgCl2, 200 M each of the four deoxynucleoside triphos-
phates, 100 pM each oligonucleotide primers, and 2.5 U
of Taq polymerase (Perkin–Elmer Cetus, Norwolk, CN) in
a hot start PCR. The template was denatured at 95°C for
3 min, and PCR amplification performed with an auto-
mated DNA thermal cycler (Perkin–Elmer Cetus) for 35
cycles of denaturation at 92°C for 1 min, annealing at
55°C for 1 min, and primer extension at 72°C for 3 min.
The reaction was completed after 10 min of primer ex-
tension at 72°C. Two microliters of resultant product was
used in the second-round PCR, using primers described
in Table 1 and conditions as described above for the
first-round PCR. Following the second round of amplifi-
cation, a 5-l aliquot was electrophoresed on a 1.5%
agarose gel, and the bands visualized by staining with
ethidium bromide.
Measurement of envelope-specific antibody
Plasma samples from vaccinated monkeys were ana-
lyzed for their reactivity to native viral glycoprotein in a
concanavalin A (Con A) ELISA, originally developed by
Robinson and co-workers (Robinson et al., 1990) and
later adapted to SIV and SHIV system by Cole and co-
workers (Cole et al., 1997a,b, 2000). Triton X-100 treated
and density gradient-purified virus (vaccine-I, vaccine-II,
or SHIVKU-2, SHIV89.6P, and SIVmacR71/17E) was used as
viral antigen and plasma from different animals were
tested for the binding antibody titers as described pre-
viously (Kumar et al., 2000).
Determination of neutralizing antibodies against
vaccine viruses
Neutralizing antibody titers in the plasma were deter-
mined by adding serial twofold dilutions of heat-inacti-
vated plasma, prepared in R-10 to flat-bottom 96-well
plates, using four wells per dilution. Eight TCID50 of
vaccine-I, vaccine-II, or SHIVKU-2 viruses were then added
to each well and the plates were incubated at 37°C for
1 h, followed by addition of 104 C8166 cells to each well.
After 1 week of incubation at 37°C, each well was scored
for CPE (Kumar et al., 2000, 2001a,b).
Development of lymphoblastoid B cell line (B-LCL)
The B lymphoblastoid cell lines (B-LCLs) were derived
by inoculating PBMCs with H. papio and maintaining the
cells for 2 weeks in the presence of 500 ng/ml of cyclo-
sporin-A (Sigma, St. Louis, MO) in 200 l R-10. Prolifer-
ating cells were transferred to tissue culture flasks and
maintained in R-10 throughout the study (Kumar et al.,
2000).
Development of autologous CD4 T cell clones
CD4 T cells from all animals were immortalized by
infection with H. saimiri. Briefly, CD8-depleted PBMCs
were inoculated with H. saimiri and maintained in R-10/
IL-2 for 1 week. The cells were then cloned by the
limiting dilution method, using irradiated human PBMCs
as feeders. Proliferating clones were cultured in R-10/IL2
and characterized by the expression of the CD4 cell-
surface marker (Kumar et al., 1999).
Generation of effector T cell populations and CTL
assays
Effectors for the CTL assays were obtained by cocul-
turing PBMC from vaccinated and control macaques with
UV-irradiated, autologous H. saimiri immortalized CD4 T
cells (HS-CD4 T cells) infected with vaccine-II virus,
SHIVKU-2, SHIV89.6P, and SIVmacR71/17E, respectively (Stipp
et al., 2000). After 3 days of coculture, the medium was
supplemented with 100 IU/ml of recombinant human
interleukin-2 (rIL-2). The cells were restimulated on day 7
with stimulators in a fashion similar as described above.
CTL activity was determined in a 4-h chromium release
assay using effectors from different animals and autolo-
gous targets. The targets included autologous HS-CD4
T cells infected with one of the vaccine or challenge
viruses, and B-LCLs infected with recombinant vaccinia
viruses expressing HIV-1-Env, SIV-Gag, or SIV-Pol. Target
cells, labeled with 100 Ci 51Cr (specific activity, 962
MBq/ml of sodium chromate, Amersham, Cleveland, OH),
were dispensed into 96-well V-bottom plates and effector
cells were tested in triplicate at effector/target (E/T) ra-
tios of 80/1, 40/1, 20/1, and 10/1. Chromium release was
determined after 4 h of incubation at 37°C by counting
100 l supernatant from each well in a Gamma counter
(Packard, Meriden, CT). Each experiment had three wells
containing 2500 targets in medium that provided data for
spontaneous lysis while three wells containing targets
and 100 l of 1% SDS provided data for maximal lysis.
The percentage specific lysis was calculated as (mean
CPM in test wells  mean CPM in spontaneous wells)/
(mean CPM in maximal wells  mean CPM in sponta-
neous wells)  100. The limitation of having only two
201LONG-TERM PROTECTION AGAINST SHIV AND SIV-INDUCED AIDS
animals in the control group in this study precluded any
statistical comparisons between the vaccinated and con-
trol animals.
Determination of virus inhibitory factor(s)
Virus-inhibitory factors were determined using a pre-
viously described protocol (Garzino-Demo et al., 1999),
with some modifications. PBMC from vaccinated and
control animals were stimulated with UV-irradiated au-
tologous CD4 T cells infected with vaccine-II and three
challenge viruses. The cells were cultured at a density of
3–3.5  106 per milliliter R-10 medium. Three days after
the initial stimulation, rIL-2 was added at a concentration
of 50 IU/ml of medium. Supernatant fluids of the cultures
from different animals were collected on day 7, centri-
fuged, and filtered through 0.45-M membrane.
To assay the effect of inhibitory factor(s), CEM174 cells
were inoculated with 104 TCID50 of vaccine-II, SHIVKU-2,
SHIV89.6P, or SIVmacR71/17E, respectively, for 2 h. The
unbound virus was removed by washing cells thrice with
R-10 medium. The cells were counted, resuspended in
R-10 medium, and cultured in triplicate in flat-bottom
96-well tissue culture plates in R-10 medium, with or
without the test supernatant fluids from individual ani-
mals. Control wells received 200 l R-10 medium,
whereas experimental wells received 100 l medium
and 100 l supernatant from each animal. On day 7, 30 l
of supernatant fluid from each well was analyzed for
virus production by the reverse transcriptase assay as
described previously (Kumar et al., 1999).
Quantitation of virus-specific CD4 and CD8 T cells
by intracellular cytokine staining
Virus-specific CD4 and CD8 T cells were quantified
by modification of a procedure described earlier (Gaud-
uin et al., 1999). Briefly, 2  106 freshly isolated PBMC
were stimulated with UV-irradiated autologous B-LCLs
that had been inoculated with a mixture of recombinant
vaccinia viruses expressing HIV-1Env, SIV-Gag, SIV-Pol,
and SIV-Nef for 12–14 h, with addition of 5 g/ml of
brefeldin-A for the last 6 h. The cells were then stained
with antibodies against CD3, CD4, CD8, and IFN-, and
analyzed on FACS calibur. In each case, the percentage
of CD4 IFN- and CD8 IFN- T cells without stim-
ulation or mock-stimulation (0.5%) was subtracted from
percentage of viral protein-specific CD4 IFN- and
CD8 IFN- T cells to calculate specific cells.
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